Young Marielle C, Banerji Aleena
From the Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts and.
Allergy Asthma Proc. 2025 May 1;46(3):185-191. doi: 10.2500/aap.2025.46.250013.
Angioedema is nonpitting swelling that involves the deeper subcutaneous and submucosal layers of tissue. Angioedema can be classified as histaminergic, bradykinin mediated, or idiopathic in etiology. Bradykinin-mediated angioedema presents without urticaria, whereas histaminergic angioedema is usually associated with urticaria (i.e., chronic spontaneous urticaria and angioedema) but manifests with isolated angioedema in ∼20% of patients and clinically overlaps with idiopathic angioedema. Bradykinin-mediated angioedema most commonly occurs in hereditary angioedema (HAE) with or without C1-esterase inhibitor (C1-INH) (HAE-C1INH) deficiency, acquired C1-INH deficiency, and angiotensin-converting enzyme (ACE) inhibitor angioedema. HAE is a life-threatening genetic autosomal dominant disorder most commonly due to a mutation in the serpin family G member 1 (SERPING1) gene, which leads to a deficiency in C1-INH, although multiple new genetic mutations have also been described in HAE with normal C1-INH (HAE-nl-C1INH) level. Clinically, patients have edema that can lead to life-threatening laryngeal edema and asphyxiation. HAE-nl-C1INH describes patients with similar symptoms to those with HAE-C1INH deficiency but have normal C1-INH function and are distinguished by various genetic mutations and a family history of angioedema. Acquired C1-INH deficiency also mimics HAE with symptoms but is due to circulating anti-idiotypic antibodies, leading to either C1-INH consumption or inactivation. Patients are often diagnosed with underlying malignant, lymphoproliferative, or autoimmune disorders. ACE-inhibitor angioedema classically presents with facial, tongue, and oral cavity swelling not associated with pruritus accompanied by normal laboratory studies. Treatment involves stopping the ACE inhibitor though recurrence can occur for a few weeks to months after discontinuation. Idiopathic angioedema is the largest category and is diagnosed when patients experience angioedema without an identifiable etiology with nl-C1INH function and no family history of angioedema. Idiopathic angioedema is further characterized into histaminergic or nonhistaminergic angioedema, depending on the response to high-dose antihistamines. Given the considerable impact of angioedema, physicians and patients must collaborate to craft personalized management strategies. For those with HAE, short- and long-term prophylaxis and on-demand therapy must be considered.
血管性水肿是一种非凹陷性肿胀,累及更深层的皮下和黏膜下层组织。血管性水肿在病因上可分为组胺能性、缓激肽介导性或特发性。缓激肽介导的血管性水肿不伴有荨麻疹,而组胺能性血管性水肿通常与荨麻疹相关(即慢性自发性荨麻疹和血管性水肿),但在约20%的患者中表现为孤立性血管性水肿,且在临床上与特发性血管性水肿重叠。缓激肽介导的血管性水肿最常见于遗传性血管性水肿(HAE),可伴有或不伴有C1酯酶抑制剂(C1-INH)(HAE-C1INH)缺乏、获得性C1-INH缺乏以及血管紧张素转换酶(ACE)抑制剂所致的血管性水肿。HAE是一种危及生命的常染色体显性遗传病,最常见的原因是丝氨酸蛋白酶抑制剂家族G成员1(SERPING1)基因发生突变,导致C1-INH缺乏,不过在C1-INH水平正常的HAE(HAE-nl-C1INH)中也描述了多种新的基因突变。临床上,患者会出现水肿,可导致危及生命 的喉头水肿和窒息。HAE-nl-C1INH描述的是症状与HAE-C1INH缺乏患者相似,但C1-INH功能正常的患者,其特征为各种基因突变和血管性水肿家族史。获得性C1-INH缺乏也表现出与HAE相似的症状,但病因是循环中的抗独特型抗体,导致C1-INH消耗或失活。患者常被诊断患有潜在的恶性、淋巴增殖性或自身免疫性疾病。ACE抑制剂所致的血管性水肿典型表现为面部、舌部和口腔肿胀,不伴有瘙痒,实验室检查结果正常。治疗包括停用ACE抑制剂,不过停药后数周 至数月可能会复发。特发性血管性水肿是最大的一类,当患者出现血管性水肿且病因不明、C1-INH功能正常且无血管性水肿家族史时可诊断为此病。根据对高剂量抗组胺药的反应,特发性血管性水肿可进一步分为组胺能性或非组胺能性血管性水肿。鉴于血管性水肿会产生重大影响,医生和患者必须共同制定个性化的管理策略。对于HAE患者,必须考虑短期和长期预防以及按需治疗。